Parenteral gold therapy in the Felty syndrome. Experience with 20 patients.
Most of the patients with the Felty syndrome suffer from such complications as fevers, infections, cutaneous ulcers, and vasculitis. Unfortunately, there are no therapeutic interventions that are predictably beneficial. We report our experience with 20 patients who received parenteral gold therapy for 2 to 114 months (mean, 23.6 months). All had complications of the Felty syndrome. On parenteral gold therapy, 60% had a complete response, 20% had a partial response, and 20% were unresponsive by preselected criteria. No serious complications were encountered. We think that parenteral gold therapy should be considered early, before other agents, in the treatment of this condition.
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D005258:Felty Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006046:Gold / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D007958:Leukocyte Count; D008875:Middle Aged; D012217:Rheumatoid Factor / Q000032:analysis
D006046:Gold; D012217:Rheumatoid Factor